A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01603095|
Recruitment Status : Enrolling by invitation
First Posted : May 22, 2012
Last Update Posted : July 16, 2020
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia|
|Study Start Date :||April 2012|
|Estimated Primary Completion Date :||October 2024|
|Estimated Study Completion Date :||February 2025|
Approximately 500 patients will be enrolled. Patients from birth to < 17 years on the date of consent will be enrolled. Approximately equal numbers of boys and girls will be enrolled.
- Collection of consistent growth measurements [ Time Frame: Assessed every 3 months for up to 84 months ]Patients will be screened and undergo a series of growth measurements on Day 1 and every 3 months thereafter. No study drug is administered.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01603095
|Study Director:||Medical Director, MD||BioMarin Pharmaceutical|